Upgrade to SI Premium - Free Trial

Jefferies Sees Limited Impact for PTC Therapeutics (PTCT) After Sarepta's Eteplirsen was Approved

September 20, 2016 9:05 AM
Jefferies analyst Gena Wang sees limited impact to PTC Therapeutics (NASDAQ: PTCT) from Sarepta Therapeutics (NASDAQ: SRPT) eteplirsen approval.Wang commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments FDA Trader Talk

Next Articles